Navigation Links
New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
Date:6/2/2008

se events included fatigue, hand/foot syndrome and skin rash.

The lead investigator for this study is Joan Schiller, MD, professor and chief of the hematology/oncology division at the University of Texas Southwestern and Andrea L. Simmons distinguished chair in cancer research, Dallas, TX. (abstract #8014).

Thyroid Cancer

A Phase 2 Study of Sorafenib in Metastatic Thyroid Carcinoma

Findings from this single-arm Phase 2 study showed that treatment with Nexavar resulted in meaningful anti-tumor activity in the majority of patients with encouraging overall clinical benefit (disease stabilization and partial responses) in patients with advanced thyroid cancer. In the study, Nexavar was well-tolerated; the most common treatment-related adverse events included fatigue, rash, diarrhea, palmer-plantar erythema, musculoskeletal pain and weight loss. Patients enrolled in this study had been diagnosed with metastatic, iodine-refractory, unresectable or locally-advanced thyroid cancer.

The lead investigator for this study is Marcia S. Brose, MD, PhD, assistant professor, director of cancer genetics laboratory, University of Pennsylvania Health System, Philadelphia, PA. (abstract #6026).

Gastrointestinal Stromal Tumors

Activity of Sorafenib in Patients with Imatinib and Sunitinib-Resistant Gastrointestinal Stromal Tumors (GIST): A Phase 2 Trial of the University of Chicago Phase 2 Consortium

Findings from this single-arm Phase 2 study suggest that Nexavar is active and well tolerated in patients with Gleevec or Gleevec and Sutent resistant GIST. The most common treatment-emergent adverse events included hand-foot syndrome, hypertension, rash and diarrhea.

The lead investigator for this study is Lauren Wiebe, MD, fellow, University of Chicago, Chicago, IL. (abstract #10502).

Gastric/GEJ

A Phase 2 Study: Combination of Sorafenib with Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Unres
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
2. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
3. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
6. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
10. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 ... Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, announced ... Japan,s Ministry of Health, Labor and ... Endomicroscopy solution, the AQ-Flex 19 miniprobe.   ... -Flex™ 19 miniprobe is comprised of a fiber-optic ...
(Date:7/6/2015)... June 29, 2015 Research ... the "Pharmaceutical Packaging Market in North America 2015-2019" ... packaging market in North America ... period 2014-2019. International regulations regarding safe ... manufacturers, which in turn fuels adoption of sustainable packaging. ...
(Date:7/6/2015)... Research and Markets( http://www.researchandmarkets.com/research/45v9b3/urinary_slings ... Slings Market in the US 2015-2019" report to ... Slings market in the US to grow at a ... This report covers the present scenario and the growth ... for the period 2015-2019. To calculate the market size, ...
Breaking Medicine Technology:Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 2North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 3United States Urinary Slings Market 2015-2019 - Vaginal Slings (TVT, TOT, and Single-incision) & Male Slings (Artificial Urinary Sphincters) 2
... CARY, N.C. , June 30 ... pharmaceutical company focused on acquiring, developing and commercializing significant ... announced the resignation of David Price , Executive ... the Company to accept a chief financial officer position ...
... SANTA ANA, Calif. , June 29 At 2 pm today, a ... where Malinda Traudt gets her medical marijuana.  But, the Court of Appeal stepped in ... (Photo: http://photos.prnewswire.com/prnh/20100518/LA07170 ) , ... (Photo: http://www.newscom.com/cgi-bin/prnh/20100518/LA07170 ) , , , ...
Cached Medicine Technology:Cornerstone Therapeutics Announces Management Change 2Cornerstone Therapeutics Announces Management Change 3Appellate Court Sides With Terminally-Ill Medical Marijuana Patient 2Appellate Court Sides With Terminally-Ill Medical Marijuana Patient 3
(Date:7/6/2015)... ... July 06, 2015 , ... The School of ... to support a three-year effort to reduce rates of diabetes and cardiovascular disease ... partnership with the Morehouse School of Medicine’s Prevention Research Center and the Satcher ...
(Date:7/6/2015)... ... ... Dr. Lawrence Green is now offering the newly FDA-approved Kybella injectable to his ... to dissolve fat cells and is the first of its kind to be approved ... known as a double chin. Dr. Green participated in clinical trials for Kybella and ...
(Date:7/6/2015)... News, VA (PRWEB) , ... July 06, 2015 ... ... today that Dr. Jeffrey R. Carlson finished his 100th case using SpineFrontier’s® PedFuse® ... Secours Mary Immaculate Hospital in Newport News, VA. The procedure was an L5-S1 ...
(Date:7/6/2015)... ... July 06, 2015 , ... Thanks to donations and a generous grant ... Music & Memory Certification for hospice patients and adult day center participants. , The ... to patients but also to their families and volunteers. Music & Memory is a ...
(Date:7/5/2015)... MN (PRWEB) , ... July 06, 2015 , ... ... the ancillary benefits market, is excited to announce the next generation of PrimeStar ... and Advantage plans to now include two network options—Maximum Allowable Charge (MAC) and ...
Breaking Medicine News(10 mins):Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 4Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2
... more than 25 countries will converge on Boston ... 2008 Annual,Conference & Exhibition. The annual event is ... in the healthcare product sector., The regulatory ... job responsibilities related to ensuring that healthcare,products in ...
... become a "difficult patient" before she could get her physicians ... , And once the diagnosis was made, she had to ... she could get the best treatment for scleroderma, a chronic ... major element. , Mayer, a research assistant professor of health ...
... Clinics of Georgia is proud to announce Dr. Chad Levitt, a ... RCOG,s Cumming, GA. Dr. Levitt specializes in head & neck, breast, ... ... Atlanta, GA. (PRWEB) September 10, 2008 -- Board Certified Radiation Oncologist ...
... specializing in risk assessment for diabetics, recently announced that The Hope ... provide retinal imaging risk assessment. , ... Wake Forest, ... Healthcare, a Wake Forest, NC company specializing in risk assessment for ...
... Steve Poizner Will Present Keynote Address at the 6th Annual California ... event is open to the public and brings together over 500 ... lively discussion, and networking. , ... Huntington Beach, CA ...
... BOSTON, Mass. (Sep. 10, 2008)In recent years, private ... investment opportunities. Spurred by investigative reports and anecdotal ... of care, many companies have found themselves under ... a new study, such conclusions may be premature. ...
Cached Medicine News:Health News:Healthcare Product Regulatory Professionals to Convene in Boston for RAPS Annual Conference & Exhibition 2Health News:Healthcare Product Regulatory Professionals to Convene in Boston for RAPS Annual Conference & Exhibition 3Health News:Survival instincts propel 'difficult patient' to insist on quality care 2Health News:Survival instincts propel 'difficult patient' to insist on quality care 3Health News:Dr. Chad Levitt Joins North Georgia Radiation Oncology Center 2Health News:Dr. Chad Levitt Joins North Georgia Radiation Oncology Center 3Health News:The Hope Clinic in Charleston, SC invests in technology to prevent vision loss in patients 2Health News:Council on Education in Management Announces Insurance Commissioner Steve Poizner Will Present Keynote Address at the 6th Annual California Workers' Comp Forum 2Health News:Private equity companies purchase nursing homes, but care does not suffer 2Health News:Private equity companies purchase nursing homes, but care does not suffer 3
An automatic system for determining erythrocyte sedimentation rate (ESR) in EDTA tube and using cell counter racks....
... of automatic systems for performing erythrocyte sedimentation ... blood. With the introduction of the Ves-matic ... market a truly revolutionary testing system which ... with the traditional ESR techique.,By means of ...
The MICROsed-System is the ideal system back up support to be used as front-line instrument with small workloads....
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
Medicine Products: